Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Angiotensin I

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Meier CM et al 2007 British Journal of Clinical Pharmacology 2007;63(5):628. Palatability of angiotensin II antagonists among nephropathic children.Meier CM et al 2007 British Journal of Clinical Pharmacology 2007;63(5):628. Palatability of angiotensin II antagonists among nephropathic children.
    Active substance: CANDESARTAN CILETEXIL
    Study summary document link (including results):
    View full study record
    Document reference: 23217
    Study title: Meier CM et al. Palatability of angiotensin II antagonists among nephropathic children. British Journal of Clinical Pharmacology 2007;63(5):628.Meier CM et al. Palatability of angiotensin II antagonists among nephropathic children. British Journal of Clinical Pharmacology 2007;63(5):628.
    Active substance: CANDESARTAN CILETEXIL
    Study summary document link (including results):
    View full study record
    Document reference: 23213
    Study title: Palatability of angiotensin II antagonists among nephropathic children. Meier CM 2007Palatability of angiotensin II antagonists among nephropathic children. Meier CM 2007
    Active substance: CANDESARTAN CILETEXIL
    Study summary document link (including results):
    View full study record
    Document reference: 23204
    Study title: Palatability, efficacy and tolerability of the angiotensin II receptor blocker (ARB) candesartan in children with hypertension or proteinuria - Simonetti GD et al 2006a Deutsche Medizinische Wochenschrift 2006;131(46)(Suppl 6):S163Palatability, efficacy and tolerability of the angiotensin II receptor blocker (ARB) candesartan in children with hypertension or proteinuria - Simonetti GD et al 2006a Deutsche Medizinische Wochenschrift 2006;131(46)(Suppl 6):S163
    Active substance: CANDESARTAN CILETEXIL
    Study summary document link (including results):
    View full study record
    Document reference: 23216
    Study title: Simonetti GD et al. Palatability, efficacy and tolerability of the angiotensin II receptor blocker (ARB) candesartan in children with hypertension or proteinuria - Palatability, efficacy and tolerability of candesartan in children. Deutsche Medizinische Wochenschrift 2006; 131(46)(Suppl 6):S163.Simonetti GD et al. Palatability, efficacy and tolerability of the angiotensin II receptor blocker (ARB) candesartan in children with hypertension or proteinuria - Palatability, efficacy and tolerability of candesartan in children. Deutsche Medizinische Wochenschrift 2006; 131(46)(Suppl 6):S163.
    Active substance: CANDESARTAN CILETEXIL
    Study summary document link (including results):
    View full study record
    Document reference: 23210
    Study title: Effectiveness and Safety of the Angiotensin II Antagonist Irbesartan in Children With Chronic Kidney Diseases
    Active substance: irbesartan
    Study summary document link (including results):
    View full study record
    Document reference: 41533
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 19:51:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA